DR. BARGHOUTHI
Dr. Taleb Barghouthi is a graduate of the Royal College of Surgeons in Ireland. Following graduation, he completed his Basic Surgical Training in Dublin and obtained his Intercollegiate Membership of the Royal College of Surgeons. He then pursued a Higher surgical training in Otolaryngology and Head and Neck Surgery at the same college. Dr. Barghouthi developed an interest in the advancing field of Hair restoration while in Ireland. He then attended a dedicated fellowship program in Hair restoration surgery in the United States. Only 5 approved programs globally offer such dedicated training in the field.
Memberships
- Intercollegiate Membership of the Royal College of Surgeons
- International Society of Hair Restoration Surgery
- American Society of Hair Restoration Surgery
- American Academy of Cosmetic Surgery
- The Trichological Society
Why has Dr Barghouthi Chosen to Research Verteporfin?
Verteporfin has the potential to improve wound healing in any surgery, in Dr Barghouthi’s case he is interested in verteporfin’s potential to improve the outcomes of hair transplant surgery. Verteporfin provides the following potential benefits to the hair loss community:
Verteporfin may significantly derisk hair transplants, as people may not have significant FUT or FUE scarring after the transplant. A significant fear of transplant patients is an inability to shave one’s head post-operation. If successful, verteporfin would mitigate that fear.
- Further, verteporfin would allow patients to avoid finasteride post-procedure, as there would be significantly less risk in shaving one’s head should they continue to bald.
- Further, verteporfin may potentially lead to partial/full donor regeneration which would lead to a larger donor supply for future operations.
Support
While Dr. Barghouthi has a responsibility to his patients in maintaining his clinical practice, he is dedicated to pursuing research in hair loss. His responsibilities limit the time available for research days and associated costs. Financial support will help accelerate research of hair restoration and scarless wound healing so that Dr. Barghouthi and his team can recruit and sponsor more patients and free up more clinic time for research. Future plans are in order to test Verteporfin further with varying doses, methods of administration, and with a FUT candidate in addition to his initial tests with FUE candidates. Each experiment varies between roughly 12,500 USD – 15,000 USD. This accounts for medication and equipment, staff operative costs, follow ups, and use of dermoscopy. Financial incentives are also offered to volunteers in return for their cooperation. Your support is wholeheartedly appreciated.
CORRESPONDENCE
Dr. Barghouthi would like to extend communication to other doctors interested in protocol development, sharing of data, and discussion of parallel execution of a test protocol matrix.
If you are interested in collaborating, please contact Dr. Barghouthi